Article: Addressing High Throughput and High Content Challenges in Drug Discovery
Traditional cell analysis platforms or dedicated single or multiplex assay systems are generally slow, offer limited analytic capabilities mandating the use of multiple platforms for comprehensive data production to meet the growing competitive pressure of the drug discovery market.
Learn how leading researchers from Dana Farber Cancer Institute, Takeda Pharmaceuticals, Kite Pharma, and LifeArc are addressing these challenges with an advanced flow cytometry platform.
